| Chiang CY |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=5.076 ------>paper_class3=2 ------>paper_class2=1 ------>vol=28 ------>confirm_bywho=chshih43 ------>insert_bywho=bkj ------>Jurnal_Rank=8.8 ------>authors4_c= ------>comm_author= ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=985 ------>medlineContent= ------>unit=E0400 ------>insert_date=20061218 ------>iam=4 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=Eur Respir J ------>paper_name=Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study ------>confirm_date=20080416 ------>tch_id=089122 ------>pmid=16837502 ------>page1=980 ------>fullAbstract=A retrospective study was performed to determine factors associated with the outcome of pulmonary multidrug-resistant tuberculosis (MDR-TB) in Taipei, Taiwan. All patients newly diagnosed with pulmonary MDR-TB in a referral centre from 1992-1996 were enrolled and their outcome over the subsequent 6 yrs was determined. A total of 299 patients were identified, comprising 215 (71.9%) males and 84 (28.1%) females with a mean age of 47.3 yrs. The patients received a mean of 3.7 effective drugs. Out of the 299 patients, 153 (51.2%) were cured, 31 (10.4%) failed, 28 (9.4%) died and 87 (29.1%) defaulted. Of the 125 patients receiving second-line drugs with ofloxacin, 74 (59.2%) were cured. Those who received ofloxacin had a lower risk of relapse than those receiving only first-line drugs (hazard ratio (HR) 0.16, 95% confidence interval (CI) 0.03-0.81) and a lower risk of TB-related death than those receiving second-line drugs but not ofloxacin (adjusted HR 0.50, 95% CI 0.31-0.82). In conclusion, multidrug-resistant tuberculosis patients who received ofloxacin were more likely to be cured, and were less likely to die, fail or relapse. The utility of new-generation fluoroquinolones, such as moxifloxacin, in the treatment of multidrug-resistant tuberculosis needs to be evaluated. Default from treatment is a major challenge in the treatment of multidrug-resistant tuberculosis. ------>tmu_sno=None ------>sno=14422 ------>authors2=Enarson D ------>authors3=Yu MC ------>authors4=Bai KJ ------>authors5=Huang RM ------>authors6=Hsu CJ, Suo J, Lin TP ------>authors6_c= ------>authors=Chiang CY ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=5 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2006 ------>submit_flag=None ------>publish_month=11 |